# EDGAR Filing Document

**Accession Number:** 0001855129
**File Stem:** 0001140361-26-007997
**Filing Date:** 2026-3
**Character Count:** 23021
**Document Hash:** 6c089d6b801152bb721dffc84dcef56a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-007997.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001140361-26-007997

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GH Research PLC
- **CENTRAL INDEX KEY:** 0001855129
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294036
- **FILM NUMBER:** 26724284

**BUSINESS ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95
- **BUSINESS PHONE:** 353 1 437 8334

**MAIL ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95

#### As filed with the Securities and Exchange Commission on March 5, 2026

#### Registration No. 333-

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

#### <br>

### FORM S-8

#### REGISTRATION STATEMENT

#### UNDER THE SECURITIES ACT OF 1933

#### <br>

------

## GH Research PLC

#### (Exact Name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **Ireland** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **N/A** |
| (State or other jurisdiction of | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (I.R.S. Employer |
| incorporation or organization) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Identification No.) |

---

#### GH Research PLC

#### Joshua Dawson House

#### Dawson Street

#### Dublin 2

#### D02 RY95

#### Ireland

#### Tel: +353 1 437 8334
(Address, including zip code, and telephone number, including area code, of Principal Executive Offices)

------

#### GH Research PLC Share Option Plan
(Full title of the plan)

------

#### Cogency Global Inc.

#### 122 East 42<sup>nd</sup> Street, 18<sup>th</sup> Floor

#### New York, NY 10168

#### Tel: (800) 221-0102
(Name, address, including zip code, and telephone number, including area code, of agent for service)

**Copies to**:

Adam Kaminsky

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, NY 10017

(212) 450-4000

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.**

---

| | |
|:---|:---|
| **Large accelerated filer ☐** | **Accelerated filer ☒** |
| **Non-accelerated filer ☐ (Do not check if a smaller reporting company)** | **Smaller reporting company ☐** |
| **Emerging Growth Company** ☒ | **Emerging Growth Company** ☒ |

---

**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.** ☐

------

#### PART I

#### REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION

Pursuant to General Instruction E to Form S-8, GH Research PLC (the "Registrant") is filing this Registration Statement on Form S-8 (this "Registration Statement") with the U.S. Securities and Exchange Commission (the "Commission") to register 1,518,547 additional ordinary shares, nominal value $0.025 per share, for issuance under the GH Research PLC Share Option Plan, as amended May 15, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Commission on March 9, 2023 (Registration No. 333-270422) and February 27, 2025 (Registration No. 333-285311).

#### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

**Item 3.** **Incorporation of Documents by Reference.**<br>

The following documents are incorporated herein by reference:

(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The annual report on [<u>Form 20-F</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/1855129/000114036126007986/ef20059887_20f.htm) of GH Research PLC (the "Registrant") for the fiscal year ended December 31, 2025, filed with the Commission on March 5, 2026; and

(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The description of the Registrant's share capital which is contained in the Registrant's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1855129/000114036121021842/nt10022430x7_8a12b.htm) (Registration No. 001-40530), dated June 22, 2021, including any amendments or supplements thereto.

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, including any Reports of Foreign Private Issuers on Form 6-K submitted during such period (or portion thereof) that is identified in such form as being incorporated by reference into this Registration Statement, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed "filed" with the Commission.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.**<br>

---

| | |
|:---|:---|
| Exhibit |  |
| Number |  |
| [4](https://www.sec.gov/Archives/edgar/data/1855129/000114036123010814/brhc10049341_ex1-1.htm) | Constitution of GH Research PLC (incorporated herein by reference to Exhibit 1.1 of the Registrant's Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Commission on March 9, 2023) |
| [5](ef20067070_ex5.htm) | Opinion of A&L Goodbody LLP (filed herewith) |
| [23.1](ef20067070_ex5.htm) | Consent of A&L Goodbody LLP (included in Exhibit 5) |
| [23.2](ef20067070_ex23-2.htm) | Consent of PricewaterhouseCoopers an independent registered public accounting firm (filed herewith) |
| [24](#POWEROFATTORNEY) | Powers of Attorney (included in the signature pages hereto) |
| [99](https://www.sec.gov/Archives/edgar/data/1855129/000114036126007986/ef20059887_ex4-1.htm) | GH Research PLC Share Option Plan, as amended May 15, 2025 (incorporated by reference to Exhibit 4.1 of the Registrant's Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Commission on March 5, 2026) |
| [107](ef20067070_ex107.htm) | Filing Fee Table |

---

------

#### SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on this 5<sup>th</sup> day of March, 2026.

---

| | |
|:---|:---|
| GH Research PLC | GH Research PLC |
| By: | /s/ Julie Ryan |
| Name:<br>| Julie Ryan |
| Title: | Vice President, Finance |

---

------

#### POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Velichka Valcheva and Julie Ryan, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ Velichka Valcheva | Chief Executive Officer | March 5, 2026 |
| Velichka Valcheva | (Principal Executive Officer) |  |
| /s/ Julie Ryan | Vice President, Finance | March 5, 2026 |
| Julie Ryan | (Principal Financial Officer and Principal Accounting Officer) |  |
| /s/ Florian Schönharting | Director | March 5, 2026 |
| Florian Schönharting |  |  |
| /s/ Michael Forer | Director | March 5, 2026 |
| Michael Forer |  |  |
| /s/ Dermot Hanley | Director | March 5, 2026 |
| Dermot Hanley |  |  |
| /s/ Duncan Moore | Director | March 5, 2026 |
| Duncan Moore |  |  |

---

------

#### SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in New York, NY on March 5, 2026.

---

| | |
|:---|:---|
| **Authorized U.S. Representative--Cogency Global Inc.** | **Authorized U.S. Representative--Cogency Global Inc.** |
| By: | /s/ Colleen A. De Vries |
|  | Name: Colleen A. De Vries |
|  | Title: Senior Vice-President on behalf of |
|  | Cogency Global Inc |

---

------

## Ex-5

------

**Exhibit 5**<br>

---

| | | |
|:---|:---|:---|
| ![](image00001.jpg) | **A&L Goodbody LLP** | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |
| ![](image00001.jpg) | 25 North Wall Quay | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |
| ![](image00001.jpg) | Dublin 1 | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |
| ![](image00001.jpg) | D01 H104 | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |
| ![](image00001.jpg) | T: +353 1 649 2000 | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |
| ![](image00001.jpg) | DX: 29 Dublin \| www.algoodbody.com | Dublin<br> Belfast<br> London<br> New York<br> San Francisco |

---

Date 05 March 2026 <br>Our ref <br> 01437848

GH Research plc

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

#### GH Research plc (the Company)

#### Registration Statement on Form S-8
Dear Sirs

We are acting as Irish counsel to the Company, a public limited company incorporated under the laws of Ireland (registered number 691405), in connection with the proposed registration by the Company of (i) 997,000 ordinary shares of the Company, nominal value $0.025 per share (the **Shares**) reserved for issuance under the GH Research PLC Share Option Plan (referred to as the **Plan**, including any amendments, restatements or sub-plan thereof) and (ii) 521,547 Shares issuable under outstanding share options previously granted under the Plan, pursuant to a Registration Statement on Form S-8 (the **Registration Statement**) to be filed by the Company with the United States Securities and Exchange Commission (**SEC**) under the Securities Act of 1933, as amended (the **Securities Act**). This Opinion is solely related to the Registration Statement.

1 In connection with this Opinion, we have examined and relied upon copies of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 such corporate records of the Company as we have deemed necessary as a basis for the opinions hereinafter expressed.

In rendering this Opinion, we have examined, and have assumed, without any responsibility on our part if any assumption proves to have been untrue as we have not verified independently any assumption, the truth and accuracy of the contents of, all such corporate records, documents and certificates of officers of the Company and of public officials as to factual matters and have conducted such searches on 5 March 2026 (being the last practicable date on which searches could be conducted) in public registries in Ireland as we have deemed necessary or appropriate for the purposes of this Opinion but have made no independent investigation regarding such factual matters. In our examination we have assumed the (continued) truth and accuracy of the information contained in such documents, the genuineness of all signatures (electronic or otherwise), that any signatures (electronic or otherwise) are the signatures of the persons who they purport to be, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such documents.

CE Gill • JG Grennan • VJ Power • SM Doggett • G O'Toole • N O'Sullivan • MJ Ward • D Widger • C Christle • S Ó Cróinin • DR Baxter • A McCarthy • JF Whelan • JB Somerville • MF Barr • AM Curran • A Roberts • RM Moore • D Main • J Cahir • PM Murray • P Walker • K Furlong • PT Fahy • M Coghlan • DR Francis • A Casey • B Hosty M O'Brien • L Mulleady • K Ryan • E Hurley • D Dagostino • R Grey • R Lyons • J Sheehy • C Carroll • SE Carson • P Diggin • J Williams • A O'Beirne • J Dallas • SM Lynch M McElhinney • C Owens • AD Ion • K O'Connor • T Casey • M Doyle • CJ Comerford • R Marron • K O'Shaughnessy • S O'Connor • SE Murphy • D Nangle • C Ó Conluain • N McMahon HP Brandt • A Sheridan • N Cole • M Devane • D Fitzgerald • G McDonald • N Meehan • R O'Driscoll • B O'Malley • C Bollard • M Daly • D Geraghty • LC Kennedy • E Mulhern MJ Ellis • D Griffin • D McElroy • C Culleton • B Nic Suibhne • S Quinlivan • J Rattigan • K Mulhern • A Muldowney • L Dunne • A Burke • C Bergin • P Fogarty • CM Carroll • E Keane D Daly Byrne • S Kearney • SE King • J Greene • C Cashin • T Glavey • E O Connor • D Broderick • K Harnett • E O'Brien • S Ahern • BP Curran • J Quirke • H Shaw E Browne • MM O'Brien • S Egan • A O'Donoghue • L HoganConsultants: Professor JCW Wylie • MA Greene • AV Fanagan • PM Law • SW Haughey • PD White<br>

------

![](image00001.jpg)

2 We have further assumed the following without any responsibility on our part if any assumption proves to have been untrue as we have not verified independently any assumption:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 that none of the resolutions and authorities of the shareholders and directors of the Company upon which we have relied have been or will be varied, amended or revoked in any respect or have expired and that the Shares will be issued in
 accordance with such resolutions and authorities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 at the time of the grant by the board of directors of the Company (the **Board**), any committee of the Board, or any other duly authorised representative of the Company, of an award or other allotment
 and issue of a Share under the Plan, (i) that the Board will be duly constituted and remain duly constituted; or (ii) that such committee will be duly constituted and remain a duly constituted committee of the Board having the necessary
 powers and authorities to grant awards and issue the Shares; or (iii) in the case of an authorised representative, that such person has the necessary powers and authorities to grant awards and issue the Shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 the Company will comply with all covenants given and representations and warranties made in connection with the Plan and that the Company will receive consideration equal to the aggregate of the nominal value and any premium required to be
 paid up on the Shares issued pursuant to awards under the Plan and that such consideration will be in cash and/or otherwise provided in accordance with Irish law.

Having made such further investigation and reviewed such other documents as we have considered requisite or desirable, subject to the foregoing and to the within additional qualifications and assumptions, we are of the opinion that:

3 the Company is a public limited company duly incorporated under the laws of Ireland and validly existing under the laws of Ireland; and

4 the Shares have been duly authorised and when issued in accordance with the terms of the Plan and the options granted or to be granted thereunder, will be validly issued, fully paid and not subject to calls for any additional payments ("nonassessable").

In rendering this Opinion we have confined ourselves to matters of Irish law. We express no opinion on any laws other than the laws of Ireland (and the interpretation thereof) in force as at the date hereof and we express no opinion with respect to taxation matters. This Opinion speaks only as of its date. We are not under any obligation to update this Opinion from time to time, nor to notify you of any change of law, facts or circumstances referred to or relied upon in the giving of this Opinion.

This Opinion is given solely for the benefit of the addressee of this Opinion and may not be relied upon by any other person without our prior written consent, provided, however, that it may be relied upon by persons entitled to rely on it pursuant to applicable provisions of US federal securities laws, including but not limited to any purchaser of the Shares.

This Opinion is intended solely for use in connection with the registration and potential issuance of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose

This Opinion is also strictly confined to the matters expressly stated herein and is not to be read as extending by implication or otherwise to any other matter.

We hereby consent to the filing of this Opinion with the SEC as an exhibit to the Registration Statement filed with the SEC on 5 March 2026 in accordance with the requirements of Item 601(b)(5) of Regulations S-K of the Securities Act.

The Opinion is governed by and construed in accordance with the laws of Ireland.

Yours faithfully

#### /s/ A&L Goodbody LLP

------

## Exhibit 23.2

------

#### Exhibit 23.2

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of GH Research PLC of our report dated March 5, 2026 relating to the financial statements, which appears in GH Research PLC 's Annual Report on Form 20-F for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers

Dublin, Ireland

March 5, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

------

**Exhibit 107**

**CALCULATION OF FILING FEE TABLE**

**FORM S-8**

 **Registration Statement Under the Securities Act of 1933**

(Form Type)

**GH Research PLC**

(Exact Name of Registrant as Specified in its Charter)

**<u>Table 1: Newly Registered Securities</u>**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered **(1)** | **Proposed Maximum Offering <br>Price Per Unit** | **Maximum Aggregate<br>Offering Price** | **Fee Rate** | &nbsp;&nbsp; **Amount of Registration Fee **(6)** |
| Equity | Ordinary Shares, nominal value $0.025 per share | 457(c) and 457(h) | 997000 (2) | $15.04 (4) | $14994880.00 | 0.00013810 | $2070.80 |
| Equity | Ordinary Shares, nominal value $0.025 per share | 457(h) | 521547 (3) | $5.39 (5) | $2811138.33 | 0.000138100.00013810 | $388.22 |
| &nbsp;&nbsp; **Total Offering Amounts** | &nbsp;&nbsp; **Total Offering Amounts** | &nbsp;&nbsp; **Total Offering Amounts** | &nbsp;&nbsp; **Total Offering Amounts** |  | $17806018.33 |  | $2459.02 |
| &nbsp;&nbsp; **Total Fee Offsets** | &nbsp;&nbsp; **Total Fee Offsets** | &nbsp;&nbsp; **Total Fee Offsets** | &nbsp;&nbsp; **Total Fee Offsets** |  |  |  |  |
| &nbsp;&nbsp; **Net Fee Due** | &nbsp;&nbsp; **Net Fee Due** | &nbsp;&nbsp; **Net Fee Due** | &nbsp;&nbsp; **Net Fee Due** |  |  |  | $2459.02 |

---

(1) This Registration
Statement on Form S-8 (this "Registration Statement") covers ordinary shares,
nominal value $0.025 per share ("Ordinary Shares"), of GH Research PLC (the
"Registrant") authorized for issuance pursuant to the GH Research PLC Share
Option Plan, as may be amended from time to time (the "Plan"). Pursuant to Rule
416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
this Registration Statement shall also cover any additional Ordinary Shares
that become issuable under the Plan by reason of any share dividend, share
split or other similar transaction.

(2) Represents Ordinary
Shares reserved for issuance pursuant to the Plan.

(3) Represents Ordinary
Shares issuable under outstanding share options granted under the Plan.

(4) Estimated solely for
the purpose of calculating the registration fee pursuant to Rules 457(c) and
457(h) under the Securities Act on the basis of the average of the high and low
sales prices reported for the Ordinary Shares on the Nasdaq Global Market on
February 27, 2026.

(5) Estimated pursuant to
Rule 457(h) under the Securities Act, solely for the purpose of computing the
registration fee, based on the weighted average exercise price of the options
outstanding under the Plan.

(6) Rounded up to the
nearest penny.

------